Medvin Clinical Research

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Rheumatoid arthritis4 trials
• Gout1 trial
• Lupus (SLE)1 trial
• Psoriasis1 trial
• Psoriatic arthritis1 trial
• Sjögren's disease1 trial

Phase

• Phase 35 trials
• Phase 11 trial
• Phase 21 trial
• Phase 41 trial

Status

• Active, not recruiting5 trials
• Completed3 trials

Lead sponsor

• Amgen2 trials
• Alfasigma S.p.A.1 trial
• Biogen1 trial
• Gilead Sciences1 trial
• Kiniksa Pharmaceuticals, Ltd.1 trial
• and 2 more

Running trials

• Active, not recruiting

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  NCT06902519· Phase 1· Gilead Sciences· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

  NCT06671483· Phase 3· Takeda· Source

• Active, not recruiting

  A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

  NCT06245408· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Biogen· Source

• Active, not recruiting

  Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

  NCT04539964· Phase 3· SetPoint Medical Corporation· Source

Closed trials

• Completed

  A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

  NCT06229145· Phase 4· Amgen· Source

• Completed

  Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

  NCT05198310· Phase 2· Kiniksa Pharmaceuticals, Ltd.· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source